recorded webinar

The Next Frontier of Mood Disorder Treatments - Psilocybin-assisted Psychotherapy

Psilocybin-assisted Psychotherapy - Mood Disorder Treatment
Thursday, January 27, 2022 12:00 pm
- 1:00 pm ET
CE/CME Credit

Member Prices


There is a recent and growing resurgence of interest in the potential for psychedelic compounds to be utilized as treatments for mood and anxiety disorders when administered in the context of a psychotherapeutic regimen. Chief among the substances most extensively studied is psilocybin, a compound originally derived from a genus of mushrooms that occurs naturally in most continents across the world. 
Though still undergoing clinical research, the Food and Drug Administration has now granted psilocybin-assisted psychotherapy the breakthrough therapy designation for the treatment of major depressive disorder. Given accumulating evidence for the efficacy of psilocybin-assisted psychotherapy in the treatment of major depressive disorder, as well as recent successful efforts to decriminalize psilocybin mushrooms and destigmatize the use of psychedelic substances for therapeutic purposes, it is increasingly likely that mental health practitioners will have the opportunity to avail themselves of this treatment modality in the near future. 
At the end of the webinar, the audience members will have a broad overview of the history, current clinical practice, and potential therapeutic mechanisms underlying psilocybin-assisted psychotherapy.

Learning Objectives:

  1. Participant will be able to describe the current state of evidence for the efficacy of psilocybin-assisted psychotherapy in the treatment of major depressive disorder and anxiety and depression secondary to life-threatening cancer.
  2. Participant will be able to describe the elements and practice of psilocybin-assisted psychotherapy that are unique to a psychedelic drug-assisted psychotherapy and that are unique from existing empirically-supported psychotherapeutic treatments.
  3. participant will be able to demonstrate basic knowledge of how psilocybin exerts effects on the brain, how these effects manifest in neuroimaging and subjective self-report measures over a temporal course, and how such effects may serve as potential neurobiological mechanisms of therapeutic benefit.
Presenter(s) Biography

Greg Fonzo, PhD

Gregory Fonzo, PhD

Greg Fonzo, PhD, is an Assistant Professor in the Department of Psychiatry at Dell Medical School with a courtesy appointment in the Department of Psychology.  He graduated summa cum laude from the University of Georgia Honors Program in 2005 with a dual bachelor’s degree in biology and psychology. He received his doctorate in clinical psychology in 2013 from the San Diego State University/University of California-San Diego Joint Doctoral Program. He completed his postdoctoral research fellowship at the Stanford University School of Medicine and the Sierra-Pacific Mental Illness Research, Education and Clinical Center (MIRECC) at the Palo Alto Veterans Affairs Healthcare System.  Dr. Fonzo’s research focuses on elucidating neurobiological mechanisms underlying manifestation and treatment of affective and stress-related disorders  and designing novel neuroscience-informed treatment modalities using tools such as neuroimaging and neuromodulation.  He is currently leading efforts at The University of Texas at Austin to understand how psychedelic-assisted psychotherapy augments neural and psychological function to alleviate mental illness and how to improve and enhance the prediction, durability, and magnitude of therapeutic benefits.

Professional Post

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.